Latest News

Using an artificial intelligence program to read echocardiograms may reduce the wait time for results and help lead to more timely medical care, according to late-breaking science presented Nov. 16 at the American Heart Association's Scientific Sessions 2024.

Seven Yale School of Medicine faculty receive Yale Faculty Innovation Awards.

Rohan Khera, MD, MS, discusses his review in the Journal of the American College of Cardiology, which highlights artificial intelligence developments in cardiovascular medicine. The review also provides an overview of future uses of AI in clinical practice and highlights areas of caution.

Yale faculty, trainees, postdocs, and students will present research at the upcoming American Heart Association Scientific Sessions in Chicago later this month.

The National Institutes of Health (NIH) recently granted Rohan Khera, MD, MS, a $3.8 million R01 award for his project, “Translating Personalized Inference from Randomized Clinical Trials to Real-World Cardiovascular Care.” This is the first systematic study to examine potential approaches to extract individualized information from randomized clinical trials.

In the first head-to-head comparison of second-line diabetes medications, researchers have identified which drugs are most effective at lowering cardiovascular disease risk.

On August 30 – September 2, Yale researchers will be presenting research and moderating sessions at the European Society of Cardiology’s (ESC) Congress 2024 in London. The focus of this year’s conference is personalizing cardiovascular care for patients.

Meet Yale clinical fellow Phyllis Thangaraj, MD, PhD, who seeks not only to practice medicine but change it.

Many patients receive a standardized lipid panel as part of a yearly physical that includes testing of their “good” cholesterol (high-density lipoprotein) and “bad” cholesterol (low-density lipoprotein). However, most people are unfamiliar with another type of cholesterol, lipoprotein(a) or Lp(a). This type of lipoprotein is not included in the standard lipid panel but is an independent risk factor for cardiovascular disease. In the following Q&A, Yale clinicians and researchers share background about Lp(a), guidance for caring for patients with elevated levels, and new approaches to improve testing.